Table 2 Cellularity of bronchoalveolar lavage fluid (BALF) and peripheral blood in all patients, survivors, non-survivors and univariate analysis
All patients (n = 64) | Survivors (n = 43) (67.2%) | Non-survivors (n = 21) 21 (32.8%) | P | |
|---|---|---|---|---|
Cellularity of BALF | ||||
Lymphocytes %, median (IQRb) | 1 (0.4–3.75) | 1 (0.3–2.25) | 1 (1–4) | 0.502 |
Neutrophils %, median (IQR) | 70 (37.5–90.5) | 71 (46–90.5) | 63 (36–83.5) | 0.408 |
Macrophages %, median (IQR) | 20 (7–42) | 20 (7–42) | 35 (16.5–56.7) | 0.194 |
TCD3+ %, median (IQR) | 92(82–95) | 92 (83–94) | 89 (79–96) | 0.873 |
TCD4+ %, median (IQR) | 30 (22–46.5) | 31 (22–47) | 29 (23–39) | 0.976 |
TCD8+ %, median (IQR) | 52 (39.5–62.7) | 53 (37–60) | 46 (42–64) | 0.995 |
TCD4+/TCD8+ Ratio | 0.6 (0.4–1.2) | 0.6 (0.4–1.2) | 0.5 (0.3–0.8) | 0.495 |
B CD19+ %, median (IQR) | 2 (1–5) | 2.5 (1–5) | 1 (1–5) | 0.205 |
Natural Killer (CD56 + CD16+) %, median (IQR) | 3 (2–10) | 5 (2–10) | 3 (2.7–13.7) | 0.618 |
Peripheral blood values at time of BALFa performing | ||||
Lymphocytes/mmc, median (IQR) | 630 (475–1000) | 900 (500–1220) | 520 (340–622) | 0.012 |
TCD4+/mmc, median (IQR) | 317 (190–534) | 358 (236–651) | 227 (152–430) | 0.100 |
TCD8+/mmc, median (IQR) | 82 (39–235) | 160 (63–267) | 44 (29–87) | 0.007 |
R TCD4+/TCD8+, median (IQR) | 4.1 (2–5.5) | 3.2 (1.4–5) | 5 (3.6–6.4) | 0.430 |